{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"CR+PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Overall tumor response is defined as the number of participants achieving either a confirmed complete or partial tumor response per Response Evaluation Criteria in Solid Tumors (RECIST). RECIST guidelines were used to evaluate the measurability of tumor lesions, to determine target and non-target lesions at Baseline, and to evaluate tumor response or disease progression after study start. CR is defined as the disappearance of all target and non-target lesions, and PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions, taking as a reference the Baseline sum LD, as assessed by the investigator. Confirmation of a CR/PR required a subsequent assessment of the same response or better at least 28 days after the original response.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From Baseline to Week 24/investigational product discontinuation (up to 3.460 years)","title":"Number of Participants With a Complete Response (CR) or Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"participants"}